1
|
Hsu CF, Liu HM, Peir JJ, Liao JW, Chen KS, Chen YW, Chuang YJ, Chou FI. Therapeutic Efficacy and Radiobiological Effects of Boric-Acid-Mediated BNCT in an Osteosarcoma-Bearing SD Rat Model. Life (Basel) 2023; 13:life13020514. [PMID: 36836871 PMCID: PMC9964381 DOI: 10.3390/life13020514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2023] [Revised: 02/02/2023] [Accepted: 02/10/2023] [Indexed: 02/15/2023] Open
Abstract
BACKGROUND Osteosarcoma (OS) is the most common primary malignancy of the bone and is notoriously resistant to radiation therapy. High-dose cytotoxic chemotherapy and surgical resection have improved the survival rate and prognosis of patients with OS. Nonetheless, treatment challenges remain when the tumor cannot be removed by surgery. Boron neutron capture therapy (BNCT) provides high linear energy transfer (LET) radiation, and its internal targeted characteristics make BNCT a novel therapy for removing OS and reducing radiation damage to adjacent healthy tissues. METHODS In this study, a UMR-106-grafted OS rat model was developed, and boric acid (BA) was used as the boron drug for BNCT. The pharmacokinetics of BA, following intravenous injection, were evaluated to determine the optimal time window for neutron irradiation. OS-bearing rats were irradiated by an epithermal neutron beam at Tsing Hua Open-Pool Reactor (THOR). The therapeutic efficacy of and tissue response after BNCT were evaluated by radiographic and histopathological observations. RESULTS OS-bearing rats were irradiated by neutrons in the first hour following the intravenous injection of BA. The prescription-absorbed doses in the tumor regions were 5.8 and 11.0 Gy. BNCT reduced the body weight of the tumor-bearing rats, but they recovered after a few days. The BA-mediated BNCT effectively controlled the orthotopic OS tumor, reduced osteolysis, and induced bone healing. Autoradiography and histological analysis confirmed that the BA retention region is consistent with the calcification region in OS tissue. CONCLUSION BA is specifically retained in OS, and the BA-mediated BNCT can significantly reduce the tumor burden and osteolysis in OS-bearing rats.
Collapse
Affiliation(s)
- Chen-Fang Hsu
- Institute of Nuclear Engineering and Science, National Tsing Hua University, Hsinchu 30013, Taiwan
| | - Hong-Ming Liu
- Nuclear Science and Technology Development Center, National Tsing Hua University, Hsinchu 30013, Taiwan
| | - Jinn-Jer Peir
- Nuclear Science and Technology Development Center, National Tsing Hua University, Hsinchu 30013, Taiwan
| | - Jiunn-Wang Liao
- Graduate Institute of Veterinary Pathobiology, College of Veterinary Medicine, National Chung Hsing University, Taichung 40227, Taiwan
| | - Kuan-Sheng Chen
- Veterinary Medical Teaching Hospital, College of Veterinary Medicine, National Chung Hsing University, Taichung 40227, Taiwan
- Department of Veterinary Medicine, College of Veterinary Medicine, National Chung Hsing University, Taichung 40227, Taiwan
| | - Yi-Wei Chen
- Department of Oncology, Taipei Veterans General Hospital, Taipei 11217, Taiwan
| | - Yung-Jen Chuang
- School of Medicine, National Tsing Hua University, Hsinchu 30013, Taiwan
- Institute of Bioinformatics and Structural Biology, National Tsing Hua University, Hsinchu 30013, Taiwan
| | - Fong-In Chou
- Institute of Nuclear Engineering and Science, National Tsing Hua University, Hsinchu 30013, Taiwan
- Nuclear Science and Technology Development Center, National Tsing Hua University, Hsinchu 30013, Taiwan
- Correspondence: ; Tel.: +886-3-5742884
| |
Collapse
|
2
|
Zandi A, Rafizadeh‐Tafti S, Shojaeian F, Ali Khayamian M, Abbasvandi F, Faranoush M, Anbiaee R, Najafikhoshnoo S, Hoseinpour P, Assadi S, Katebi P, Davari sh. Z, Shalileh S, Salemizadeh Parizi M, Vanaei S, Ghaderinia M, Abadijoo H, Taheri P, Reza Esmailinejad M, Sanati H, Reza Rostami M, Sadeghian R, Kordehlachin Y, Sadegh Mousavi‐kiasary SM, Mamdouh A, Hossein Miraghaie S, Baharvand H, Abdolahad M. Positive electrostatic therapy of metastatic tumors: selective induction of apoptosis in cancer cells by pure charges. Cancer Med 2021; 10:7475-7491. [PMID: 34626092 PMCID: PMC8559484 DOI: 10.1002/cam4.4267] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2021] [Revised: 08/04/2021] [Accepted: 08/17/2021] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND We discovered that pure positive electrostatic charges (PECs) have an intrinsic suppressive effect on the proliferation and metabolism of invasive cancer cells (cell lines and animal models) without affecting normal tissues. METHODS We interacted normal and cancer cell lines and animal tumors with PECs by connecting a charged patch to cancer cells and animal tumors. many biochemical, molecular and radiological assays were carried out on PEC treated and control samples. RESULTS Correlative interactions between electrostatic charges and cancer cells contain critical unknown factors that influence cancer diagnosis and treatment. Different types of cell analyses prove PEC-based apoptosis induction in malignant cell lines. Flowcytometry and viability assay depict selective destructive effects of PEC on malignant breast cancer cells. Additionally, strong patterns of pyknotic apoptosis, as well as downregulation of proliferative-associated proteins (Ki67, CD31, and HIF-1α), were observed in histopathological and immunohistochemical patterns of treated mouse malignant tumors, respectively. Quantitative real-time polymerase chain reaction results demonstrate up/down-regulated apoptotic/proliferative transcriptomes (P21, P27, P53/CD34, integrin α5, vascular endothelial growth factor, and vascular endothelial growth factor receptor) in treated animal tumors. Expression of propidium iodide in confocal microscopy images of treated malignant tissues was another indication of the destructive effects of PECs on such cells. Significant tumor size reduction and prognosis improvement were seen in over 95% of treated mouse models with no adverse effects on normal tissues. CONCLUSION We discovered that pure positive electrostatic charges (PECs) have an intrinsic suppressive effect on the proliferation and metabolism of invasive cancer cells (cell lines and animal models) without affecting normal tissues. The findings were statistically and observationally significant when compared to radio/chemotherapy-treated mouse models. As a result, this nonionizing radiation may be used as a practical complementary approach with no discernible side effects after passing future human model studies.
Collapse
Affiliation(s)
- Ashkan Zandi
- Nanobioelectronic Devices Lab.Cancer Electronics Research GroupSchool of Electrical and Computer EngineeringFaculty of EngineeringUniversity of TehranTehranIran
- Nano Electronic Center of ExcellenceNanoelectronics and Thin Film Lab.School of Electrical and Computer EngineeringFaculty of EngineeringUniversity of TehranTehranIran
| | - Saeid Rafizadeh‐Tafti
- Nanobioelectronic Devices Lab.Cancer Electronics Research GroupSchool of Electrical and Computer EngineeringFaculty of EngineeringUniversity of TehranTehranIran
| | - Fatemeh Shojaeian
- Nanobioelectronic Devices Lab.Cancer Electronics Research GroupSchool of Electrical and Computer EngineeringFaculty of EngineeringUniversity of TehranTehranIran
- School of MedicineShahid Beheshti University of Medical SciencesTehranIran
| | - Mohammad Ali Khayamian
- Nanobioelectronic Devices Lab.Cancer Electronics Research GroupSchool of Electrical and Computer EngineeringFaculty of EngineeringUniversity of TehranTehranIran
| | - Fereshteh Abbasvandi
- ATMP DepartmentBreast Cancer Research CenterMotamed Cancer InstituteACECRTehranIran
| | - Mohammad Faranoush
- Pediatric Growth and Development Research CenterInstitute of Endocrinology and MetabolismIran University of Medical SciencesTehranIran
- Cardio‐Oncology Research CenterRajaie Cardiovascuar Medical & Research CenterIran University of Medical SciencesTehranIran
| | - Robab Anbiaee
- Department of Radiation OncologyImam Hossein HospitalShahid Beheshti University of Medical SciencesTehranIran
| | - Sahar Najafikhoshnoo
- Nanobioelectronic Devices Lab.Cancer Electronics Research GroupSchool of Electrical and Computer EngineeringFaculty of EngineeringUniversity of TehranTehranIran
| | | | - Sepanta Assadi
- Nanobioelectronic Devices Lab.Cancer Electronics Research GroupSchool of Electrical and Computer EngineeringFaculty of EngineeringUniversity of TehranTehranIran
| | - Pouyan Katebi
- Nanobioelectronic Devices Lab.Cancer Electronics Research GroupSchool of Electrical and Computer EngineeringFaculty of EngineeringUniversity of TehranTehranIran
| | - Zahra Davari sh.
- Nanobioelectronic Devices Lab.Cancer Electronics Research GroupSchool of Electrical and Computer EngineeringFaculty of EngineeringUniversity of TehranTehranIran
| | - Shahriar Shalileh
- Nanobioelectronic Devices Lab.Cancer Electronics Research GroupSchool of Electrical and Computer EngineeringFaculty of EngineeringUniversity of TehranTehranIran
| | - Mohammad Salemizadeh Parizi
- Nanobioelectronic Devices Lab.Cancer Electronics Research GroupSchool of Electrical and Computer EngineeringFaculty of EngineeringUniversity of TehranTehranIran
| | - Shohreh Vanaei
- Nanobioelectronic Devices Lab.Cancer Electronics Research GroupSchool of Electrical and Computer EngineeringFaculty of EngineeringUniversity of TehranTehranIran
| | - Mohammadreza Ghaderinia
- Nanobioelectronic Devices Lab.Cancer Electronics Research GroupSchool of Electrical and Computer EngineeringFaculty of EngineeringUniversity of TehranTehranIran
| | - Hamed Abadijoo
- Nanobioelectronic Devices Lab.Cancer Electronics Research GroupSchool of Electrical and Computer EngineeringFaculty of EngineeringUniversity of TehranTehranIran
| | - Payam Taheri
- Department of Stem Cells and Developmental BiologyCell Science Research CenterRoyan Institute for Stem Cell Biology and TechnologyACECRTehranIran
| | | | - Hassan Sanati
- ATMP DepartmentBreast Cancer Research CenterMotamed Cancer InstituteACECRTehranIran
| | - Mohammad Reza Rostami
- Nanobioelectronic Devices Lab.Cancer Electronics Research GroupSchool of Electrical and Computer EngineeringFaculty of EngineeringUniversity of TehranTehranIran
| | - Reza Sadeghian
- Nanobioelectronic Devices Lab.Cancer Electronics Research GroupSchool of Electrical and Computer EngineeringFaculty of EngineeringUniversity of TehranTehranIran
| | - Yasin Kordehlachin
- Nanobioelectronic Devices Lab.Cancer Electronics Research GroupSchool of Electrical and Computer EngineeringFaculty of EngineeringUniversity of TehranTehranIran
| | - S. M. Sadegh Mousavi‐kiasary
- Nanobioelectronic Devices Lab.Cancer Electronics Research GroupSchool of Electrical and Computer EngineeringFaculty of EngineeringUniversity of TehranTehranIran
| | - Amir Mamdouh
- Nanobioelectronic Devices Lab.Cancer Electronics Research GroupSchool of Electrical and Computer EngineeringFaculty of EngineeringUniversity of TehranTehranIran
| | - Seyyed Hossein Miraghaie
- Nanobioelectronic Devices Lab.Cancer Electronics Research GroupSchool of Electrical and Computer EngineeringFaculty of EngineeringUniversity of TehranTehranIran
| | - Hossein Baharvand
- Department of Stem Cells and Developmental BiologyCell Science Research CenterRoyan Institute for Stem Cell Biology and TechnologyACECRTehranIran
- Department of Developmental BiologyUniversity of Science and CultureTehranIran
| | - Mohammad Abdolahad
- Nanobioelectronic Devices Lab.Cancer Electronics Research GroupSchool of Electrical and Computer EngineeringFaculty of EngineeringUniversity of TehranTehranIran
- Nano Electronic Center of ExcellenceNanoelectronics and Thin Film Lab.School of Electrical and Computer EngineeringFaculty of EngineeringUniversity of TehranTehranIran
- Cancer InstituteImam Khomeini HospitalTehran University of Medical SciencesTehranIran
- UT&TUMS Cancer electronic Research CenterTehran University of Medical SciencesTehranIran
| |
Collapse
|
3
|
Lan T, Xue X, Dunmall LC, Miao J, Wang Y. Patient-derived xenograft: a developing tool for screening biomarkers and potential therapeutic targets for human esophageal cancers. Aging (Albany NY) 2021; 13:12273-12293. [PMID: 33903283 PMCID: PMC8109069 DOI: 10.18632/aging.202934] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2020] [Accepted: 03/23/2021] [Indexed: 04/15/2023]
Abstract
Esophageal cancer (EC) represents a human malignancy, diagnosed often at the advanced stage of cancer and resulting in high morbidity and mortality. The development of precision medicine allows for the identification of more personalized therapeutic strategies to improve cancer treatment. By implanting primary cancer tissues into immunodeficient mice for expansion, patient-derived xenograft (PDX) models largely maintain similar histological and genetic representations naturally found in patients' tumor cells. PDX models of EC (EC-PDX) provide fine platforms to investigate the tumor microenvironment, tumor genomic heterogeneity, and tumor response to chemoradiotherapy, which are necessary for new drug discovery to combat EC in addition to optimization of current therapeutic strategies for EC. In this review, we summarize the methods used for establishing EC-PDX models and investigate the utilities of EC-PDX in screening predictive biomarkers and potential therapeutic targets. The challenge of this promising research tool is also discussed.
Collapse
Affiliation(s)
- Tianfeng Lan
- Sino-British Research Center for Molecular Oncology, National Center for the International Research in Cell and Gene Therapy, School of Basic Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, P.R. China
| | - Xia Xue
- Sino-British Research Center for Molecular Oncology, National Center for the International Research in Cell and Gene Therapy, School of Basic Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, P.R. China
- The Academy of Medical Science, Precision Medicine Center of the Second Affiliated Hospital of Zhengzhou University, Zhengzhou University, Henan, P.R. China
| | - Louisa Chard Dunmall
- Centre for Cancer Biomarkers and Biotherapeuitcs, Barts Cancer Institute, Queen Mary University of London, London, UK
| | - Jinxin Miao
- Sino-British Research Center for Molecular Oncology, National Center for the International Research in Cell and Gene Therapy, School of Basic Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, P.R. China
- Academy of Chinese Medicine Science, Henan University of Chinese Medicine, Zhengzhou, Henan, P.R. China
| | - Yaohe Wang
- Sino-British Research Center for Molecular Oncology, National Center for the International Research in Cell and Gene Therapy, School of Basic Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan, P.R. China
- Centre for Cancer Biomarkers and Biotherapeuitcs, Barts Cancer Institute, Queen Mary University of London, London, UK
| |
Collapse
|
4
|
Sánchez-Céspedes R, Accornero P, Miretti S, Martignani E, Gattino F, Maniscalco L, Gola C, Iussich S, Martano M, Morello E, Buracco P, Aresu L, Maria RD. In vitro and in vivo effects of toceranib phosphate on canine osteosarcoma cell lines and xenograft orthotopic models. Vet Comp Oncol 2019; 18:117-127. [PMID: 31816142 DOI: 10.1111/vco.12562] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2019] [Revised: 11/21/2019] [Accepted: 11/25/2019] [Indexed: 02/01/2023]
Abstract
Canine osteosarcoma (OSA) is the most common primary malignant bone tumour in dogs, and it has a high metastatic rate and poor prognosis. Toceranib phosphate (TOC; Palladia, Zoetis) is a veterinary tyrosine kinase inhibitor that selectively inhibits VEGFR-2, PDGFRs and c-Kit, but its efficacy is not yet fully understood in the treatment of canine OSA. Here, we evaluated the functional effects of TOC on six OSA cell lines by transwell, wound healing and colony formation assays. Subsequently, two cell lines (Wall and Penny) were selected and were inoculated in mice by intrafemoral injection to develop an orthotopic xenograft model of canine OSA. For each cell line, 30 mice were xenografted; half of them were used as controls, and the other half were treated with TOC at 40 mg/kg body weight for 20 days. TOC inhibited cell growth of all cell lines, but reduced invasion and migration was only observed in Penny and Wall cell lines. In mice engrafted with Penny cells and subjected to TOC treatment, decreased tumour growth was observed, and PDGFRs and c-Kit mRNA were downregulated. Immunohistochemical analyses demonstrated a significant reduction of Ki67 staining in treated mice when compared to controls. The results obtained here demonstrate that TOC is able to slightly inhibit cell growth in vitro, while its effect is evident only in a Penny cell xenograft model, in which TOC significantly reduced tumour size and the Ki67 index without modifying apoptosis markers.
Collapse
Affiliation(s)
- Raquel Sánchez-Céspedes
- Department of Comparative Pathology, Veterinary Faculty, University of Córdoba, Córdoba, Spain
| | - Paolo Accornero
- Department of Veterinary Science, University of Turin, Grugliasco, Italy
| | - Silvia Miretti
- Department of Veterinary Science, University of Turin, Grugliasco, Italy
| | - Eugenio Martignani
- Department of Veterinary Science, University of Turin, Grugliasco, Italy
| | - Francesca Gattino
- Department of Veterinary Science, University of Turin, Grugliasco, Italy
| | - Lorella Maniscalco
- Department of Veterinary Science, University of Turin, Grugliasco, Italy
| | - Cecilia Gola
- Department of Veterinary Science, University of Turin, Grugliasco, Italy
| | - Selina Iussich
- Department of Veterinary Science, University of Turin, Grugliasco, Italy
| | - Marina Martano
- Department of Veterinary Science, University of Turin, Grugliasco, Italy
| | - Emanuela Morello
- Department of Veterinary Science, University of Turin, Grugliasco, Italy
| | - Paolo Buracco
- Department of Veterinary Science, University of Turin, Grugliasco, Italy
| | - Luca Aresu
- Department of Veterinary Science, University of Turin, Grugliasco, Italy
| | - Raffaella De Maria
- Department of Veterinary Science, University of Turin, Grugliasco, Italy
| |
Collapse
|
5
|
Shekhar TM, Burvenich IJG, Harris MA, Rigopoulos A, Zanker D, Spurling A, Parker BS, Walkley CR, Scott AM, Hawkins CJ. Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice. BMC Cancer 2019; 19:924. [PMID: 31521127 PMCID: PMC6744692 DOI: 10.1186/s12885-019-6103-5] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Accepted: 08/28/2019] [Indexed: 12/14/2022] Open
Abstract
Background Current therapies fail to cure over a third of osteosarcoma patients and around three quarters of those with metastatic disease. “Smac mimetics” (also known as “IAP antagonists”) are a new class of anti-cancer agents. Previous work revealed that cells from murine osteosarcomas were efficiently sensitized by physiologically achievable concentrations of some Smac mimetics (including GDC-0152 and LCL161) to killing by the inflammatory cytokine TNFα in vitro, but survived exposure to Smac mimetics as sole agents. Methods Nude mice were subcutaneously or intramuscularly implanted with luciferase-expressing murine 1029H or human KRIB osteosarcoma cells. The impacts of treatment with GDC-0152, LCL161 and/or doxorubicin were assessed by caliper measurements, bioluminescence, 18FDG-PET and MRI imaging, and by weighing resected tumors at the experimental endpoint. Metastatic burden was examined by quantitative PCR, through amplification of a region of the luciferase gene from lung DNA. ATP levels in treated and untreated osteosarcoma cells were compared to assess in vitro sensitivity. Immunophenotyping of cells within treated and untreated tumors was performed by flow cytometry, and TNFα levels in blood and tumors were measured using cytokine bead arrays. Results Treatment with GDC-0152 or LCL161 suppressed the growth of subcutaneously or intramuscularly implanted osteosarcomas. In both models, co-treatment with doxorubicin and Smac mimetics impeded average osteosarcoma growth to a greater extent than either drug alone, although these differences were not statistically significant. Co-treatments were also more toxic. Co-treatment with LCL161 and doxorubicin was particularly effective in the KRIB intramuscular model, impeding primary tumor growth and delaying or preventing metastasis. Although the Smac mimetics were effective in vivo, in vitro they only efficiently killed osteosarcoma cells when TNFα was supplied. Implanted tumors contained high levels of TNFα, produced by infiltrating immune cells. Spontaneous osteosarcomas that arose in genetically-engineered immunocompetent mice also contained abundant TNFα. Conclusions These data imply that Smac mimetics can cooperate with TNFα secreted by tumor-associated immune cells to kill osteosarcoma cells in vivo. Smac mimetics may therefore benefit osteosarcoma patients whose tumors contain Smac mimetic-responsive cancer cells and TNFα-producing infiltrating cells.
Collapse
Affiliation(s)
- Tanmay M Shekhar
- Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria, 3086, Australia
| | - Ingrid J G Burvenich
- Tumour Targeting Laboratory, Ludwig Institute for Cancer Research and Olivia Newton-John Cancer Research Institute, Melbourne, Australia.,School of Cancer Medicine, La Trobe University, Melbourne, Australia
| | - Michael A Harris
- Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria, 3086, Australia
| | - Angela Rigopoulos
- Tumour Targeting Laboratory, Ludwig Institute for Cancer Research and Olivia Newton-John Cancer Research Institute, Melbourne, Australia.,School of Cancer Medicine, La Trobe University, Melbourne, Australia
| | - Damien Zanker
- Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria, 3086, Australia
| | - Alex Spurling
- Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria, 3086, Australia
| | - Belinda S Parker
- Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria, 3086, Australia
| | - Carl R Walkley
- St. Vincent's Institute, Fitzroy, Victoria, 3065, Australia.,Department of Medicine, St. Vincent's Hospital, University of Melbourne, Fitzroy, Victoria, 3065, Australia.,Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Victoria, 3000, Australia
| | - Andrew M Scott
- Tumour Targeting Laboratory, Ludwig Institute for Cancer Research and Olivia Newton-John Cancer Research Institute, Melbourne, Australia.,School of Cancer Medicine, La Trobe University, Melbourne, Australia.,Departments of Medical Oncology and Molecular Imaging & Therapy, Austin Health, Heidelberg, Melbourne, Australia.,Department of Medicine, University of Melbourne, Melbourne, Australia
| | - Christine J Hawkins
- Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Victoria, 3086, Australia.
| |
Collapse
|
6
|
Scott MC, Tomiyasu H, Garbe JR, Cornax I, Amaya C, O'Sullivan MG, Subramanian S, Bryan BA, Modiano JF. Heterotypic mouse models of canine osteosarcoma recapitulate tumor heterogeneity and biological behavior. Dis Model Mech 2016; 9:1435-1444. [PMID: 27874835 PMCID: PMC5200896 DOI: 10.1242/dmm.026849] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2016] [Accepted: 09/23/2016] [Indexed: 01/03/2023] Open
Abstract
Osteosarcoma (OS) is a heterogeneous and rare disease with a disproportionate impact because it mainly affects children and adolescents. Lamentably, more than half of patients with OS succumb to metastatic disease. Clarification of the etiology of the disease, development of better strategies to manage progression, and methods to guide personalized treatments are among the unmet health needs for OS patients. Progress in managing the disease has been hindered by the extreme heterogeneity of OS; thus, better models that accurately recapitulate the natural heterogeneity of the disease are needed. For this study, we used cell lines derived from two spontaneous canine OS tumors with distinctly different biological behavior (OS-1 and OS-2) for heterotypic in vivo modeling that recapitulates the heterogeneous biology and behavior of this disease. Both cell lines demonstrated stability of the transcriptome when grown as orthotopic xenografts in athymic nude mice. Consistent with the behavior of the original tumors, OS-2 xenografts grew more rapidly at the primary site and had greater propensity to disseminate to lung and establish microscopic metastasis. Moreover, OS-2 promoted formation of a different tumor-associated stromal environment than OS-1 xenografts. OS-2-derived tumors comprised a larger percentage of the xenograft tumors than OS-1-derived tumors. In addition, a robust pro-inflammatory population dominated the stromal cell infiltrates in OS-2 xenografts, whereas a mesenchymal population with a gene signature reflecting myogenic signaling dominated those in the OS-1 xenografts. Our studies show that canine OS cell lines maintain intrinsic features of the tumors from which they were derived and recapitulate the heterogeneous biology and behavior of bone cancer in mouse models. This system provides a resource to understand essential interactions between tumor cells and the stromal environment that drive the progression and metastatic propensity of OS. Editors' choice: We developed a system that recapitulates the heterogeneous biological behavior of bone cancer in mouse models and describe novel methods to study tumor–stromal interactions in these models.
Collapse
Affiliation(s)
- Milcah C Scott
- Animal Cancer Care and Research Program, University of Minnesota, St Paul, MN 55108, USA.,Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St Paul, MN 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
| | - Hirotaka Tomiyasu
- Animal Cancer Care and Research Program, University of Minnesota, St Paul, MN 55108, USA.,Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St Paul, MN 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
| | - John R Garbe
- Minnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN 55455, USA
| | - Ingrid Cornax
- Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.,Department of Veterinary Population Medicine, College of Veterinary Medicine, University of Minnesota, St Paul, MN 55108, USA
| | - Clarissa Amaya
- Department of Biomedical Sciences, Center of Emphasis in Cancer Research at the Paul Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA
| | - M Gerard O'Sullivan
- Animal Cancer Care and Research Program, University of Minnesota, St Paul, MN 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.,Department of Veterinary Population Medicine, College of Veterinary Medicine, University of Minnesota, St Paul, MN 55108, USA
| | - Subbaya Subramanian
- Animal Cancer Care and Research Program, University of Minnesota, St Paul, MN 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.,Department of Surgery, School of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
| | - Brad A Bryan
- Department of Biomedical Sciences, Center of Emphasis in Cancer Research at the Paul Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA
| | - Jaime F Modiano
- Animal Cancer Care and Research Program, University of Minnesota, St Paul, MN 55108, USA .,Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St Paul, MN 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.,Stem Cell Institute, University of Minnesota, Minneapolis, MN 55455, USA.,Center for Immunology, University of Minnesota, Minneapolis, MN 55455, USA
| |
Collapse
|
7
|
Kubicek L, Vanderhart D, Wirth K, An Q, Chang M, Farese J, Bova F, Sudhyadhom A, Kow K, Bacon NJ, Milner R. ASSOCIATION BETWEEN COMPUTED TOMOGRAPHIC CHARACTERISTICS AND FRACTURES FOLLOWING STEREOTACTIC RADIOSURGERY IN DOGS WITH APPENDICULAR OSTEOSARCOMA. Vet Radiol Ultrasound 2016; 57:321-30. [PMID: 26916056 DOI: 10.1111/vru.12351] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2014] [Revised: 11/07/2015] [Accepted: 11/09/2015] [Indexed: 11/29/2022] Open
Abstract
The objective of this observational, descriptive, retrospective study was to report CT characteristics associated with fractures following stereotactic radiosurgery in canine patients with appendicular osteosarcoma. Medical records (1999 and 2012) of dogs that had a diagnosis of appendicular osteosarcoma and undergone stereotactic radiosurgery were reviewed. Dogs were included in the study if they had undergone stereotactic radiosurgery for an aggressive bone lesion with follow-up information regarding fracture status, toxicity, and date and cause of death. Computed tomography details, staging, chemotherapy, toxicity, fracture status and survival data were recorded. Overall median survival time (MST) and fracture rates of treated dogs were calculated. CT characteristics were evaluated for association with time to fracture. Forty-six dogs met inclusion criteria. The median overall survival time was 9.7 months (95% CI: 6.9-14.3 months). The fracture-free rates at 3, 6, and 9 months were 73%, 44%, and 38% (95% CI: 60-86%, 29-60%, and 22-54%), respectively. The region of bone affected was significantly associated with time to fracture. The median time to fracture was 4.2 months in dogs with subchondral bone involvement and 16.3 months in dogs without subchondral bone involvement (P-value = 0.027, log-rank test). Acute and late skin effects were present in 58% and 16% of patients, respectively. Findings demonstrated a need for improved patient selection for this procedure, which can be aided by CT-based prognostic factors to predict the likelihood of fracture.
Collapse
Affiliation(s)
- Lyndsay Kubicek
- Department of Small Animal Clinical Sciences, University of Florida, Gainesville, FL, 32611.,Angell Animal Medical Center, Jamaica Plain, MA, Boston, MA, 02130
| | - Daniel Vanderhart
- Department of Small Animal Clinical Sciences, University of Florida, Gainesville, FL, 32611
| | - Kimberly Wirth
- Department of Small Animal Clinical Sciences, University of Florida, Gainesville, FL, 32611
| | - Qi An
- Department of Biostatistics, University of Florida, Gainesville, FL, 32611
| | - Myron Chang
- Department of Biostatistics, University of Florida, Gainesville, FL, 32611
| | - James Farese
- Pet Emergency and Specialty Center of Marin, San Rafael, CA, 94901
| | - Francis Bova
- Department of Neurosurgery, McKnight Brain Institute, University of Florida, Gainesville, FL, 32611
| | - Atchar Sudhyadhom
- the Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94143
| | - Kelvin Kow
- Department of Small Animal Clinical Sciences, University of Florida, Gainesville, FL, 32611
| | - Nicholas J Bacon
- Department of Small Animal Clinical Sciences, University of Florida, Gainesville, FL, 32611
| | - Rowan Milner
- Department of Small Animal Clinical Sciences, University of Florida, Gainesville, FL, 32611
| |
Collapse
|
8
|
Schwartz AL, Custis JT, Harmon JF, Powers BE, Chubb LS, LaRue SM, Ehrhart NP, Ryan SD. Orthotopic model of canine osteosarcoma in athymic rats for evaluation of stereotactic radiotherapy. Am J Vet Res 2013; 74:452-8. [PMID: 23438123 DOI: 10.2460/ajvr.74.3.452] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To develop an orthotopic model of canine osteosarcoma in athymic rats as a model for evaluating the effects of stereotactic radiotherapy (SRT) on osteosarcoma cells. ANIMALS 26 athymic nude rats. PROCEDURES 3 experiments were performed. In the first 2 experiments, rats were injected with 1 × 10(6) Abrams canine osteosarcoma cells into the proximal aspect of the tibia (n = 12) or distal aspect of the femur (6). Tumor engraftment and progression were monitored weekly via radiography, luciferase imaging, and measurement of urine pyridinoline concentration for 5 weeks and histologic evaluation after euthanasia. In the third experiment, 8 rats underwent canine osteosarcoma cell injection into the distal aspect of the femur and SRT was administered to the affected area in three 12-Gy fractions delivered on consecutive days (total radiation dose, 36 Gy). Percentage tumor necrosis and urinary pyridinoline concentrations were used to assess local tumor control. The short-term effect of SRT on skin was also evaluated. RESULTS Tumors developed in 10 of 12 tibial sites and all 14 femoral sites. Administration of SRT to rats with femoral osteosarcoma was feasible and successful. Mean tumor necrosis of 95% was achieved histologically, and minimal adverse skin effects were observed. CONCLUSIONS AND CLINICAL RELEVANCE The orthotopic model of canine osteosarcoma in rats developed in this study was suitable for evaluating the effects of local tumor control and can be used in future studies to evaluate optimization of SRT duration, dose, and fractionation schemes. The model could also allow evaluation of other treatments in combination with SRT, such as chemotherapy or bisphosphonate, radioprotectant, or parathyroid hormone treatment.
Collapse
Affiliation(s)
- Anthony L Schwartz
- Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA
| | | | | | | | | | | | | | | |
Collapse
|